Building speciality portfolio of around 150 products in next 3 fiscal yrs: Aurobindo

Aurobindo Pharma is focussing on building a diverse speciality portfolio of nearly 150 products with an addressable market size of USD 118.2 billion in the next three financial years, the drug firm said in an investor presentation on Monday.

The speciality portfolio will be in various therapeutic segments such as oncology and hormones, biologics, topicals, nasals, peptides, depot injection, inhalers, vaccines and transdermal patches totalling 147 products under development.
In a regulatory filing to BSE, the company said 79 products are under development in oncology and hormones, 22 are in topicals, 5 are in nasals, 14 are in peptides and 4 in depot injection segment.
The other products under development are 8 in transdermal patches, 8 in inhalers, 6 in biologics and one in vaccines, it added.
While largest addressable market size is USD 45 billion for oncology and hormones segment, it is USD 35 billion for biologics and USD 12.2 billion for peptides segment, the presentation said.
The addressable market size is USD 7.5 billion for inhalers, USD 6.2 billion for vaccines, USD 5 billion for topicals, USD 3.6 billion for depot injection, USD 3.2 billion for transdermal patches and USD 0.5 billion for nasals, it added.
The revenue generation will start from first quarter of 2019-20 for oncology and hormones, from 2020-21 for topicals, from 2019-20/2020-21 for nasals, from 2020-21 for peptides and from 2021-22 for depot injections, it added.
The revenue generation will start from 2020-21 for transdermal patches, from 2021-22 for inhalers, from 2021-22 for biologics and from 2021-22 for vaccines, the presentation said.
Commenting on the filing targets, Aurobindo said it plans to file all products over next 3 years in the oncology and hormones segment.

In topicals, it is looking to file all products over next 2-3 years.

For nasals, the company plans to file all products by 2019-20. While in the peptides segment the company plans to file 5 more DMFs over next 18 months, it plans to file all products by 2021-22 for the depot injection segment.

The company plans to file all products over next 3 years in transdermal patches. It is planning to file all products over next 3 years in inhalers, to file first set of products by 2021-22 in biologics and vaccine by 2020-21, Aurobindo Pharma said.
For nasals, the company plans to file all products by 2019-20. While in the peptides segment the company plans to file 5 more DMFs over next 18 months, it plans to file all products by 2021-22 for the depot injection segment.

The company plans to file all products over next 3 years in transdermal patches. It is planning to file all products over next 3 years in inhalers, to file first set of products by 2021-22 in biologics and vaccine by 2020-21, Aurobindo Pharma said.

Source:https://www.business-standard.com/article/pti-stories/building-speciality-portfolio-of-around-150-products-in-next-3-fiscal-yrs-aurobindo-119010700671_1.html

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more